Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.
Fouquet G, Guidez S, Richez V, Stoppa AM, Le Tourneau C, Macro M, Gruchet C, Bobin A, Moya N, Syshenko T, Sabirou F, Levy A, Franques P, Gardeney H, Karlin L, Benboubker L, Ouali M, Vedovato JC, Ferre P, Pavlyuk M, Attal M, Facon T, Leleu X.
Fouquet G, et al. Among authors: vedovato jc.
Oncotarget. 2018 May 8;9(35):23890-23899. doi: 10.18632/oncotarget.25156. eCollection 2018 May 8.
Oncotarget. 2018.
PMID: 29844860
Free PMC article.